Pursuant to regulations 30 & 33 of SEBI (LODR), we inform that the Board at its meeting held on November 11, 2025, approved: 1. Un-audited & Standalone Financial results for the quarter ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivanza Biosciences reported a sharp jump in standalone revenue from operations to Rs. 5,373.18 lakhs in Q2 FY26, up from Rs. 158.33 lakhs in Q2 FY25, with H1 FY26 revenue at Rs. 6,155.24 lakhs versus Rs. 201.11 lakhs a year earlier. Standalone profit after tax rose to Rs. 46.21 lakhs (Q2 FY26) from Rs. 0.53 lakhs (Q2 FY25), translating to EPS of Rs. 0.12. The auditor (Shivam Soni & Co.) issued an unmodified limited review report with no qualifications. The Board also approved a postal ballot to alter the company's objects clause to add plastic polymer films, plastic/paper bags, and flexible packaging business, appointed CS Chaitra Arora as the new Company Secretary (replacing CS Siddhi Shah who resigned on September 26, 2025), and fixed November 7, 2025 as the cut-off date for the postal ballot.
The dramatic revenue surge reflects a shift into trading/distribution activities (purchases of stock-in-trade of Rs. 5,516 lakhs closely mirror revenue), keeping margins razor-thin and driving negative operating cash flow of Rs. 56.20 lakhs in H1 FY26 despite accounting profit. Shareholders should watch margin sustainability and the proposed diversification into packaging, which could reshape the business but is subject to postal ballot approval.